Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Lucy Y. Liu"'
Autor:
Samvel Gyurdzhyan, Vijaytha Muralidharan, Lucy Y. Liu, John B. Sunwoo, Lisa C. Zaba, Susan M. Swetter
Publikováno v:
Skin Health and Disease, Vol 4, Iss 1, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/2f9d5bf4593d4696b7c2472cc48e635b
Autor:
Lucy Y. Liu
Publikováno v:
Nota Bene, Vol 2, Iss 1 (2011)
Externí odkaz:
https://doaj.org/article/fd8c2fbeab75439aa06bdc8b4b10adfc
Autor:
LUCY Y. LIU
Publikováno v:
Music Analysis. 41:50-93
Autor:
Benjamin D. Solomon, Meliha Skaljic, Lucy Y. Liu, Di Yan, Kathleen M. Sheahon, Lori Broderick, Hal M. Hoffman, Shannon J. Beres, Ryanne A. Brown, Joyce M.C. Teng, Yael Gernez
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 11:941-942
Publikováno v:
Journal of Investigative Dermatology Symposium Proceedings. 20:S37-S40
Alopecia areata affects not only scalp hair but also other sites of body hair, including eyebrows. Our objective was to investigate the importance of eyebrows in the treatment goals of patients with alopecia areata. Through an online questionnaire, s
Publikováno v:
Pediatric Blood & Cancer. 68
Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper managemen
Publikováno v:
Journal of Vascular Anomalies. 3:e047
Autor:
Lucy Y. Liu, Brett A. King
Publikováno v:
Journal of the American Academy of Dermatology. 80:566-568
Publikováno v:
Journal of the American Academy of Dermatology. 76:29-32
Background There are no reliably effective therapies for alopecia areata (AA). Objective We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA. Methods We revi
Publikováno v:
Journal of the American Academy of Dermatology. 76:22-28
Background Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. Objective We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an